John Valliant

2021

In 2021, John Valliant earned a total compensation of $3.3M as Chief Executive Officer at Fusion Pharmaceuticals, a 53% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$259,699
Option Awards$2,384,726
Salary$597,010
Other$31,332
Total$3,272,768

Valliant received $2.4M in option awards, accounting for 73% of the total pay in 2021.

Valliant also received $259.7K in non-equity incentive plan, $597K in salary and $31.3K in other compensation.

Rankings

In 2021, John Valliant's compensation ranked 4,092nd out of 12,412 executives tracked by ExecPay. In other words, Valliant earned more than 67.0% of executives.

ClassificationRankingPercentile
All
4,092
out of 12,412
67th
Division
Manufacturing
1,687
out of 5,498
69th
Major group
Chemicals And Allied Products
697
out of 2,374
71st
Industry group
Drugs
620
out of 2,095
70th
Industry
Biological Products, Except Diagnostic Substances
163
out of 452
64th
Source: SEC filing on April 29, 2022.

Valliant's colleagues

We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2021.

2021

Eric Burak

Fusion Pharmaceuticals

Chief Scientific Officer

2021

John Crowley

Fusion Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like